FCGR2B and systemic lupus erythematosus: We intraperitoneally injected symptomatic Fcgr2b−/− mice (5–6 months old) with ISD017 or cyclophosphamide to determine whether ISD017 can be used as a treatment for overt lupus phenotypes compared to the standard treatment, cyclophosphamide (Fig. 1A).